SCHEMBL5229765

SCHEMBL5229765

COCCNCc1ccc(-c2nc3c(C)nn(-c4ccccc4)c3c(=O)[nH]2)c(OC)c1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDE7A Q13946 2/20 0.44
PDE7B Q9NP56 1/20 0.44
PDE5A O76074 2/20 0.43
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 2/20 0.40
LMNA P02545 1/20 0.40
HPGD P15428 1/20 0.40
HSD17B10 Q99714 1/20 0.40
MAPT P10636 2/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
GPR55 Q9Y2T6 1/20 0.38
HEXA P06865 1/20 0.37
HEXB P07686 1/20 0.37
TP53 P04637 2/20 0.37
CCNE1 P24864 1/20 0.37
CDK2 P24941 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5232028 0.86 CFTR (0.46) PDE7APDE7BPDE5AKDM4EHSD17B10
SCHEMBL5233350 0.82 PDE7A (0.44) PDE7APDE7BPDE5A
SCHEMBL5232197 0.82 PDE7A (0.49) PDE7APDE7BPDE5AHPGDMAPT
SCHEMBL5229748 0.82 PDE7A (0.68) PDE7APDE7B
SCHEMBL5237338 0.82 PDE7A (0.50) PDE7APDE7BPDE5AMAPTTP53
SCHEMBL5231578 0.80 PDE7A (0.49) PDE7APDE7BPDE5A
SCHEMBL5232006 0.80 PDE7A (0.65) PDE7APDE7BPDE5A
SCHEMBL5233250 0.80 PDE7A (0.50) PDE7APDE7BPDE5AKDM4EALDH1A1
SCHEMBL5229120 0.80 PDE7A (0.50) PDE7APDE7BPDE5AMEN1KMT2A
SCHEMBL5234499 0.80 PDE5A (0.48) PDE7APDE7BPDE5AALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1454897-B1 PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7-INHIBITORY ACTIVITY ASUBIO PHARMA CO LTD (JP) 2007-10-10 EP disclosed
US-7268128-B2 1,3,5-trisubstituted-5-phenyl and 5-pyridyl pyrazolopyrimidinone derivatives having PDE7 inhibiting action AUSBIO PHARMA CO., LTD. (JP) 2007-09-11 US disclosed
US-20050148604-A1 Pyrazolopyrimidinone derivatives having PDE7 inhibiting action OMEROS CORPORATION 2005-07-07 US disclosed
EP-1454897-A1 PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7−INHIBITORY ACTIVITY Daiichi Suntory Pharma Co., Ltd. (JP) 2004-09-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148604-A1 Pyrazolopyrimidinone derivatives having PDE7 inhibiting action PDE7B, PDE3B, PDE3A PDE7A 4/4885PDE7B 1/4885PDE5A 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.